scholarly journals A36: Long-term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis

2014 ◽  
Vol 66 ◽  
pp. S55-S56 ◽  
Author(s):  
Jocelyn H. Leu ◽  
Alan Mendelsohn ◽  
Joyce Ford ◽  
Hugh M. Davis ◽  
Honghui Zhou ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Pediatric Patients ◽  
Polyarticular Juvenile Idiopathic Arthritis

scholarly journals Nuclear medicine in the pediatric field

2021 ◽  
pp. 36-65
Author(s):  
Barone Sebastiano ◽  
Pagliuso Serena
Keyword(s):  
Nuclear Medicine ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
European Association ◽  
Pediatric Patients ◽  
Target Organ ◽  
Organ Weight ◽  
Reference Levels ◽  
Medical Examinations

The work presented describes the main ways of preparing radiopharmaceuticals and carrying out nuclear-medical examinations in pediatric patients. Through the differences in the execution of the tests, the importance of dosimetry is revealed, i.e. the diagnostic reference levels, in which the percentage of activity that must be administered to the child on the basis of that introduced in the adult is indicated. Through a study performed on pediatric patients, subjected to nuclear-medical investigations, the validity of the LDRs is reported according to the scheme in tab. 6 (EANM-EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE). Through a study conducted in pediatric patients, subjected to medical - nuclear investigations, the importance of the dose is noted in order to obtain greater benefits in the patient and high quality images for diagnostic purposes. By carrying out pediatric-radiopharmaceutical calculations, it is possible to reproduce the aforementioned, ie an optimization of the dose. Using body surface area Child's body surface area (m2) _______________________________ = 0.53g: 1.8 g = 29% - 2.9 mCi Adult's body surface area (m2) Using organ weight Target organ weight of child (g) = 93 g: 310g = 30% - 3.0 mCi Target organ weight of adult (g)

Providing Mechanical Support to Children Size and Anatomical Considerations

2019 ◽  
pp. 246-254
Author(s):  
Kyle W. Riggs ◽  
David L. S. Morales
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Management Strategies ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Mechanical Support ◽  
Ventricular Assist ◽  
Small Children

Mechanical circulatory support (MCS) in children has changed greatly during the past two decades. Historically, extracorporeal membranous oxygenation was the only mechanical support option for children. The introduction and widespread use of the Berlin Heart EXCOR pump—a pulsatile, pneumatic compression device still commonly used in small children—allowed the use of ventricular assist devices (VAD). This chapter describes the leading MCS options in small children with complex pathology and reviews the evolution of cannulation strategies for long-term support. It describes an advanced imaging technique that allows devices to be “virtually fit” to patients before implantation, a technology that may increase the number of eligible patients receiving devices thought to be too large by body surface area alone. Although body imaging is required, virtual fit will supplant the antiquated use of weight and body surface area in planning complicated implantations. Finally, the chapter presents MCS management strategies for different congenital anomalies, such as single-ventricle pathology and arterial transpositions.

Pharmacokinetics (PK) of bendamustine in pediatric patients with relapsed/refractory acute leukemia.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9547-9547
Author(s):  
Mona Darwish ◽  
Gail C. Megason ◽  
Mary Bond ◽  
Edward Hellriegel ◽  
Philmore Robertson ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Pediatric Patients ◽  
Systemic Exposure ◽  
The Body ◽  
Adult Patients ◽  
Concentration Data ◽  
Pharmaceutical Industries

9547 Background: The PK profile of bendamustine in adult patients is well characterized. The objective of this analysis was to describe the pediatric PK profile of bendamustine relative to the adult PK profile and correlate the systemic exposure of bendamustine to efficacy and safety parameters. Methods: Samples were obtained after a single dose from patients aged 1-19 years with relapsed/refractory acute leukemia who were enrolled in an open-label, nonrandomized study of bendamustine (90–120 mg/m2, infused over 60 minutes). Samples were obtained prior to bendamustine infusion and preselected time points through 24 hours after start of infusion on day 1. Population PK modeling was performed using plasma concentration data from these patients. PK data from adults were used for comparison. Results: Systemic exposure of pediatric patients to bendamustine was similar to that obtained previously in adult patients. Mean Cmax was 6806 ng/mL and mean AUC0-24 was 8240 ng*hr/mL in pediatric patients, compared with a mean Cmax of 5746 ng/mL and AUC0-24 of 7121 ng*hr/mL in adults. Similarity in exposure despite the large range of body surface area across the pediatric and adult populations confirms appropriateness of the body surface area–based dosing scheme. In pediatric patients, age, race, sex, or disease state had no statistically significant effect on systemic exposure to bendamustine. No changes in systemic exposure to bendamustine in the presence of a CYP1A2 inhibitor/inducer were observed. Differences in PK were not observed in pediatric patients with mild renal impairment as compared with patients with normal renal function. Exposure in 2 pediatric patients with moderate hepatic dysfunction appeared to be higher. No clear exposure-response relationship was observed. Infection was the only adverse event for which the probability of occurrence increased with increase in exposure to bendamustine. Conclusions: The PK profile of bendamustine in pediatric patients was similar to the known PK profile in adults, demonstrating that exposures reflective of the therapeutic range in adults were attained following administration of 120 mg/m2 to pediatric patients. Support: Teva Pharmaceutical Industries Ltd., Frazer, PA.

Long-Term Psychosocial Adaptation of Children Who Survive Burns Involving 80% or Greater Total Body Surface Area

1998 ◽  
Vol 44 (4) ◽  
pp. 625-634 ◽  
Author(s):  
Patricia Blakeney ◽  
Walter Meyer ◽  
Rhonda Robert ◽  
Manubhai Desai ◽  
Steven Wolf ◽  
...  
Keyword(s):  
Surface Area ◽  
Body Surface Area ◽  
Body Surface ◽  
Total Body Surface Area ◽  
Psychosocial Adaptation ◽  
Total Body

Mexican Patient with Refractory Mycosis Fungoides Successfully Treated with Pralatrexate at Low Doses: Case Report

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5068-5068
Author(s):  
Jose R Lopez
Keyword(s):  
T Cell ◽  
Surface Area ◽  
Body Surface Area ◽  
Mycosis Fungoides ◽  
Body Surface ◽  
Sézary Syndrome ◽  
Sezary Syndrome ◽  
Low Doses ◽  
Mexican Patient

Abstract Introduction Primary cutaneous lymphomas (PCL) are defined as non-Hodgkin lymphomas. They are found in the skin without an extra primary cutaneous location at the moment of diagnosis1. Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T-cell lymphomas, MF represents less than 1% of the total number of non-Hodgkin lymphomas1,2,3; however, it is the most common cutaneous lymphoma2. It usually has an indolent course and good prognosis when identified in its early stages3. Therefore, treatment should be reaching the optimal benefit with minimizing the toxicity as much as possible. The therapeutic approaches for patients with PCL depend on the disease stage; skin-directed therapies are generally used, with systemic treatments reserved for patients with relapsed or more extensive disease. However durable remissions off-therapy are uncommon in MF/SS and, historically, more aggressive first-line approaches have not resulted in improved outcomes, but are associated with increased toxicity3. The moderate response rates and frequent lack of durable responses to current therapies for PCL underline the need for additional effective and tolerable treatments. This case represent the first Mexican patient treated successfully with low doses of pralatrexate as monotherapy, achieving almost complete response. Case The patient is a 40 years old male with history of skin tumoral lesions that previously was diagnosed as primary anaplastic lymphoma, however, in a skin biopsy and immunohistochemistry it was identified Mycosis fungoides. The classical type of MF has 4 stages: patch, plaque, tumoral and erythroderma or Sézary syndrome. Of them, the most common is the patch/plaque MF, which presents with extremely pruritic, erythematous macules and patches with telangiectasias and atrophy in the "bathing trunk" distribution2. In this case initially the patient presented with plaque and tumoral lesions in 45% of body surface area. Mostly in thorax, face and arms, highly symptomatic and aesthetically unpleasant. He was initially managed with PUVA and topical corticosteroids, followed by CHOP-R with bad response to both treatments. The treatment was changed to bortezomib and interferon with limited response. Then it was decided to change treatment to pralatrexate at low doses (according to Mexican guidelines of NHL treatment) 15 mg/m2 as monotherapy in cycles of 10 weeks (6 weeks on treatment and 4 off treatment). After the initial dosage of pralatrexate the patient manifested decrease of the symptoms, by the end of the first cycle the improvement was observed in approximately 20% of body surface area. The adverse reactions presented were fatigue, paresthesia at the site of administration and nausea, all of them were mild and not required additional treatment. Currently the patient has completed 3 cycles of pralatrexate showing improvement of cutaneous involvement in 35% of body surface area. Discussion None of the current therapeutic options available for patients with PCL are curative. Many patients are treated sequentially and suffer from frequent morbidity because of the burden of their disease and the cumulative toxicity of therapy3. Published papers have identified an effective PCL dosing regimen for pralatrexate with a safety profile that is acceptable for continuous long-term use4. In this case this regimen was adapted to the patient and it represents the first experience in Mexico using pralatrexate for Mycosis fungoides. The patient has shown favorable and rapid response to therapy, diminishing symptoms and disease activity. Pralatrexate appears to be a promising agent for the treatment of patients with refractory MF. Yamashita T, Abbade LP, Marques ME, Marques SA. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. An Bras Dermatol 2012; 87: 817-28Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009; 114: 4337-53Al Hothali GI. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach. Int J Health Sci (Qassim) 2013; 7: 220-39Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012; 119: 4115-22 Disclosures Lopez: Mundipharma: Other: Subsidies for the costs of travel to the ASH annual meeting. Off Label Use: Pralatrexate is approved at a dose of 30mg/m2. In this case I administer a low dose (15 mg/m2) to improve tolerance and maintain in a long term the treatment..

Sign in / Sign up

Export Citation Format

Share Document